WuXi passes FDA muster in China and amps up its U.S. presence

Chinese outsourcing giant WuXi PharmaTech ($WX) passed an FDA audit at one of its local facilities and broke ground on a new plant in the U.S., executing on its two-pronged strategy to take a bigger share of the global drug development market. In China, WuXi's Shanghai analytical and stability testing facilities passed an FDA inspection, which the company said could speed up approvals for clients. Meanwhile, WuXi is getting started on the construction of a 45,000-square-foot cell therapy manufacturing facility in Philadelphia, planning to cut the ribbon on the plant by the second quarter of 2015. Shanghai | Philadelphia

Suggested Articles

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

After delisting from the New York Stock Exchange, WuXi AppTec has received regulatory approval to be listed in Shanghai.